Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/bmri/volume-2015/865101/figures/865101.fig.002a.svgz" name="865101.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Clinical trial reviews</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/bmri/volume-2015/865101/figures/865101.fig.002b.svgz" name="865101.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>HTA reports</td></tr></table>

<div>Clinical endpoints used for the different tumor types in (a) clinical trial review papers and (b) health technology assessment reports.</div>

BioMed Research International

fig2

Figure 2

Figure 2: Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? 